Update on Maintenance Immunosuppression in Intestinal Transplantation.
Intestinal transplantation
Maintenance immunosuppression
Vedolizumab
Journal
Gastroenterology clinics of North America
ISSN: 1558-1942
Titre abrégé: Gastroenterol Clin North Am
Pays: United States
ID NLM: 8706257
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
medline:
28
7
2024
pubmed:
28
7
2024
entrez:
27
7
2024
Statut:
ppublish
Résumé
Outcomes in intestinal transplantation remain hampered by higher rates of rejection than any other solid organs. However, maintenance immunosuppression regimens have largely remained unchanged despite advances in therapies for induction and treatment of rejection and graft-versus-host disease. Recently, there have been a small number of new maintenance therapies attempted, and older agents have been used in new ways to achieve better outcomes. The authors herein review the traditional maintenance therapies and their mechanisms and then consider updates in new therapies and new ways of using old therapies for maintenance immunosuppression after intestinal transplantation.
Identifiants
pubmed: 39068010
pii: S0889-8553(23)00130-9
doi: 10.1016/j.gtc.2023.12.007
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-507Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors declare no commercial or financial conflicts of interest.